November 3, 2007 -- Last week, Regenerx was awarded a patent in China for its Thymosin beta 4 (TB4) products that treat eye degeneration associated with dry eye syndrome; Tongjitang reported positive results from a two-year, western-style clinical trial of its TCM for osteoporosis; Benda formed a joint venture with DNAVEC to develop a gene-therapy based therapeutic vaccine for HIV; TPG invested more than $30 million in ShangPharma; Novartis will construct a $700 million biotech manufacturing facility in Singapore; Roche will spend $100 million to build a second R&D center in China; MDS moved to a larger lab in Beijing; Dragon Pharma developed a new, less expensive biotech production process for its Cephalosporin intermeidates; and a bill that re-authorized the FDA in the US sidestepped the political minefield of follow-on biologics (FOBs). More details...
